β-hCG vaccine | The Contraceptive Pipeline Database

Product Overview

Alternative Name: β-human chorionic gonadotropin

Development Status: Active Development

Target: Female

Mode: Non-hormonal

Delivery Type: TBD

Duration Type: Long-acting

Description: β-human chorionic gonadotropin (β-hCG) is a candidate immunogens to develop immunocontraceptive vaccine for human application.

Updated date: May 30, 2018

Vertical Tabs

Product Details

Potential Multi-Purpose Technology (MPT): No

Partner: Talwar Research Foundation, Indian Council for Medical Research

Status

Project Phase: Late Development

Project Stage: Phase II

Status Details:
Phase II trials were completed in 1994. After a phase of inactivity, work began on a recombinant vaccine, which could be amenable to industrial production. Preclinical work on the reconfigured vaccine has been undertaken and there are plans to restart clinical trials.

Programmatic Considerations

Additional Information

Additional Information:
Talwar GP, et al. (1994) A vaccine that prevents pregnancy in women. Proc Natl Acad Sci. 30;91(18):8532-6.

Talwar GP, et al. (2015) Advances in development of a contraceptive vaccine against human chorionic gonadotropin. Expert Opinion on Biological Therapy. 15:8.

Footnotes:
See also entry on CTP of β-hCG vaccine.

Download Product Report